Testing a new antifungal for mold infections in immunocompromised people
Part of Infections clinical trials.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a weakened immune system (due to a stem cell or bone marrow transplant, blood cancer, recent low white blood cell count for more than 10 days, long-term steroid use, or an inherited immune disorder).
- You have a suspected or proven mold infection, based on a lab test or a chest CT scan.
- You have not received more than 4 days of antifungal treatment for this infection before the study starts.
- You do not have severe liver, kidney, heart, or lung problems, and you are not on dialysis.
- If you are a woman who can become pregnant, you must use highly effective birth control and have negative pregnancy tests; men must use a condom or be vasectomized.
- You are willing to come for study visits and follow all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
This trial tests the safety and effectiveness of a medicine called liposomal amphotericin B for treating serious mold infections in liver transplant recipients. It compares this medicine to another antifungal called voriconazole, and may help find the best way to treat these infections after a liver transplant.
This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
This study uses noninvasive breathing/relates imaging (MRI or CT) to help diagnose mold infections in the lungs in children and young adults. It may help doctors find these infections sooner, especially in people with weakened immune systems.
Hear when a new Invasive Mould Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.